Form 4: Gilead Sciences CEO Sells Shares
Insider Transaction (Form 4)
Daniel Patrick O'Day, Chairman & CEO and a Director of Gilead Sciences, Inc., sold 15,000 shares of common stock on September 1, 2026.
Summary
- Open-market sale: disposed of 1,600 Common Stock at $147.51 ($236,014) on September 1, 2026; holds 590,533 after (Direct).
- Open-market sale: disposed of 7,992 Common Stock at $148.36 ($1,185,722) on September 1, 2026; holds 582,541 after (Direct).
- Open-market sale: disposed of 5,408 Common Stock at $149.38 ($807,856) on September 1, 2026; holds 577,133 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,229,592 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Daniel Patrick O'Day — Director, Officer (Chairman & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Open-market sale | Common Stock | 1,600 | $148 | $236.0K | 590,533 |
| 2026-09-01 | Open-market sale | Common Stock | 7,992 | $148 | $1.2M | 582,541 |
| 2026-09-01 | Open-market sale | Common Stock | 5,408 | $149 | $807.9K | 577,133 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Open-market sale (1,600 shares) |
| 2026-09-01 | Open-market sale (7,992 shares) |
| 2026-09-01 | Open-market sale (5,408 shares) |
Keywords
insider transaction, Form 4, GILD, GILEAD SCIENCES, INC., bearish, Daniel Patrick O'Day
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.